医疗并购热潮再起！传强生洽购百亿市值生物制药新星Intra-Cellular

智通财经01-13

1月13日，据知情人士透露，强生公司正在洽谈收购专注于治疗中枢神经系统疾病的生物制药公司Intra-Cellular Therapies Inc.，双方最早可能在本周达成协议，尽管谈判仍在进行中，但可能不会达成协议，也可能出现其他竞购者。对此，强生公司的一位代表拒绝发表评论，而Intra-Cellular的发言人未能立即联系到发表评论。如果宣布，这笔交易将成为一年多以来最大的生物技术交易，凸显...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2503196753?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","is_english":false,"pubTime":"2025-01-13 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503196753","market":"us","top_or_hot":-1,"title":"医疗并购热潮再起！传强生洽购百亿市值生物制药新星Intra-Cellular","media":"智通财经","content":"<div>\n<p>1月13日，据知情人士透露，强生公司正在洽谈收购专注于治疗中枢神经系统疾病的生物制药公司Intra-Cellular Therapies Inc.，双方最早可能在本周达成协议，尽管谈判仍在进行中，但可能不会达成协议，也可能出现其他竞购者。对此，强生公司的一位代表拒绝发表评论，而Intra-Cellular的发言人未能立即联系到发表评论。如果宣布，这笔交易将成为一年多以来最大的生物技术交易，凸显...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1236521.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>医疗并购热潮再起！传强生洽购百亿市值生物制药新星Intra-Cellular</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n医疗并购热潮再起！传强生洽购百亿市值生物制药新星Intra-Cellular\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-13 14:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1236521.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1月13日，据知情人士透露，强生公司正在洽谈收购专注于治疗中枢神经系统疾病的生物制药公司Intra-Cellular Therapies Inc.，双方最早可能在本周达成协议，尽管谈判仍在进行中，但可能不会达成协议，也可能出现其他竞购者。对此，强生公司的一位代表拒绝发表评论，而Intra-Cellular的发言人未能立即联系到发表评论。如果宣布，这笔交易将成为一年多以来最大的生物技术交易，凸显...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1236521.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1914381329.SGD","symbol_name":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1236521.html","article_id":"2503196753","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503196753","pubTimestamp":1736748019,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，据知情人士透露，强生公司正在洽谈收购专注于治疗中枢神经系统疾病的生物制药公司Intra-Cellular Therapies Inc.，双方最早可能在本周达成协议，尽管谈判仍在进行中，但可能不会达成协议，也可能出现其他竞购者。对此，强生公司的一位代表拒绝发表评论，而Intra-Cellular的发言人未能立即联系到发表评论。此前，强生公司剥离了消费者健康部门，并以131亿美元收购了心脏设备制造商Shockwave Medical，现在又重新发起攻势。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","BK4504":"桥水持仓","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","BK4559":"巴菲特持仓","ITCI":"Intra-Cellular Therapies Inc.","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","BK4550":"红杉资本持仓","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","BK4532":"文艺复兴科技持仓","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","BK4581":"高盛持仓","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","JNJ":"强生"},"translate_title":"The boom of medical mergers and acquisitions is resurfacing! Johnson & Johnson is rumored to be negotiating to purchase Intra-Cellular, a rising biopharmaceutical star with a market value of tens of billions","themeId":"7f3dbc5d0b8695149db5783f6a9d05c0","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/e9fcde8bb307feb99cf8e2f692c02f0b","symbols_score_info":{"ITCI":1,"JNJ":1},"content_text":"1月13日，据知情人士透露，强生公司正在洽谈收购专注于治疗中枢神经系统疾病的生物制药公司Intra-Cellular Therapies Inc.，双方最早可能在本周达成协议，尽管谈判仍在进行中，但可能不会达成协议，也可能出现其他竞购者。对此，强生公司的一位代表拒绝发表评论，而Intra-Cellular的发言人未能立即联系到发表评论。如果宣布，这笔交易将成为一年多以来最大的生物技术交易，凸显医疗保健交易在2024年下滑后再次升温，当时大型制药公司放缓了疫情后的交易热潮以消化收购。本月，医疗设备制造商史赛克(SYK.US)同意以约49亿美元收购Inari Medical(NARI.US)。据了解，过去12个月，Intra-Cellular的股价上涨了约40%，公司市值达到约100亿美元。Intra-Cellular开发了治疗精神疾病和神经系统疾病的新疗法，目前正在研发一种治疗重度抑郁症的药物，该药物正处于后期试验阶段。此外，Intra-Cellular上周曾表示已与Sandoz达成和解协议，以解决与其治疗双相抑郁症的药物Caplyta相关的专利诉讼，此后该公司股价大涨。相比之下，强生公司股价在12个月内下跌了约12%，市值为3420亿美元。此前，强生公司剥离了消费者健康部门，并以131亿美元收购了心脏设备制造商Shockwave Medical，现在又重新发起攻势。该公司正面临失去牛皮癣治疗药物Stelara的独家经营权的风险，因此一直在努力保持增长。强生制药部门全球业务发展主管Nauman Shah 6月在BIO国际大会上接受采访时表示：“我们当然仍然拥有财力和实力，无论交易规模如何。”“如果这些交易有意义，我们将更加关注这五笔交易，甚至可以称之为200亿美元的交易。”强生公司的讨论是在旧金山举行的医疗保健行业年度会议前夕进行的。虽然时间不确定，但公司通常会在摩根大通医疗保健会议前后宣布交易。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2503196753","isCrawlerRequest":true}